ReviewFrontiers in microbiology2020
Tackling Multidrug Resistance in Streptococci - From Novel Biotherapeutic Strategies to Nanomedicines.
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Effects of Metal and Metal Oxide Nanoparticles against Biofilm-Forming Bacteria: A Systematic Review.Journal of microbiology and biotechnology · 2024Pooled it
- Anti-Streptococcal Activity of β-Thujaplicin and Its Effect on Natural Low-Level Resistance ofPathogens (Basel, Switzerland) · 2026Article
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- Interspecies signaling can sensitize intrinsically resistant Streptococcus pyogenes to colistin.Molecular biology reports · 2025Article
- Revolutionizing oronasal fistula treatment inOpen veterinary journal · 2025Article
- The Role of Plant Oils in Combating Streptococcal Infections: Mechanisms, Efficacy, and Therapeutic Potential.Current microbiology · 2025Review
- Development of a small compound that regulates the function of a maltodextrin-binding protein of Streptococcus pyogenes by multifaceted screenings.Scientific reports · 2025Article
- Antimicrobial Activity, Genetic Diversity and Safety Assessment of Lactic Acid Bacteria Isolated from European Hakes (Antibiotics (Basel, Switzerland) · 2025Article
- Characterization ofFrontiers in microbiology · 2025Article
- Biomedical Promise of Aspergillus Flavus-Biosynthesized Selenium Nanoparticles: A Green Synthesis Approach to Antiviral, Anticancer, Anti-Biofilm, and Antibacterial Applications.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Isolation of phages against Streptococcus species in the oral cavity for potential control of dental diseases and associated systemic complications.Archives of microbiology · 2024Article
- Prevalence, Antibiotic Susceptibility Pattern and Associated Factors ofInternational journal of microbiology · 2024Article
- Streptococcus dysgalactiae subsp. dysgalactiae presents with progressive weakness in limbs: a case report and literature review.BMC infectious diseases · 2023Review
- Cell membrane-coated nanoparticles: An emerging antibacterial platform for pathogens of food animals.Frontiers in veterinary science · 2023Review
- Antibiotic-resistant status and pathogenic clonal complex of canine Streptococcus canis-associated deep pyoderma.BMC veterinary research · 2022Article
- Ionic Liquids: Emerging Antimicrobial Agents.Pharmaceutical research · 2022Review
- Multidrug-Resistant Bacterial Pathogens and Public Health: The Antimicrobial Effect of Cyanobacterial-Biosynthesized Silver Nanoparticles.Antibiotics (Basel, Switzerland) · 2022Article
- Antibacterial pyrazoles: tackling resistant bacteria.Future medicinal chemistry · 2022Review
- Light Triggered Enhancement of Antibiotic Efficacy in Biofilm Elimination Mediated by Gold-Silver Alloy Nanoparticles.Frontiers in microbiology · 2022Article
- Endolysins against Streptococci as an antibiotic alternative.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pyogenic streptococci group includes pathogenic species for humans and other animals and has been associated with enduring morbidity and high mortality. The main reason for the treatment failure of streptococcal infections is the increased resistance to antibiotics. In recent years, infectious diseases caused by pyogenic streptococci resistant to multiple antibiotics have been raising with a significant impact to public health and veterinary industry. The rise of antibiotic-resistant streptococci has been associated to diverse mechanisms, such as efflux pumps and modifications of the antimicrobial target. Among streptococci, antibiotic resistance emerges from previously sensitive populations as result of horizontal gene transfer or chromosomal point mutations due to excessive use of antimicrobials. Streptococci strains are also recognized as biofilm producers. The increased resistance of biofilms to antibiotics among streptococci promote persistent infection, which comprise circa 80% of microbial infections in humans. Therefore, to overcome drug resistance, new strategies, including new antibacterial and antibiofilm agents, have been studied. Interestingly, the use of systems based on nanoparticles have been applied to tackle infection and reduce the emergence of drug resistance. Herein, we present a synopsis of mechanisms associated to drug resistance in (pyogenic) streptococci and discuss some innovative strategies as alternative to conventional antibiotics, such as bacteriocins, bacteriophage, and phage lysins, and metal nanoparticles. We shall provide focused discussion on the advantages and limitations of agents considering application, efficacy and safety in the context of impact to the host and evolution of bacterial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.